To identify key prognostic biomarkers and potential therapeutic targets for kidney renal clear cell carcinoma (KIRC) through multi-omics integrative analysis and preliminary experimental validation.
Key Findings:
Include specific statistical results for CRHBP's prognostic value.
Clarify the context of UCN2's correlation with tumor angiogenesis and hypoxia.
Interpretation:
Remove unsupported claims about the CRHBP-UCN2 axis.
Limitations:
Rephrase for clarity regarding biases in public databases.
Specify the biological complexities not encompassed by preliminary validation.
Conclusion:
Remove unsupported claims about CRHBP as a potential anticancer peptide target.
